Misplaced Pages

Promin

Clinical data
Other names	Sodium glucosulfone, Aceprosol, Promanide, Tasmin, Sulfona P
Identifiers
IUPAC name 2,3,4,5,6-pentahydroxy-1-phenyl]sulfonylanilino]hexane-1-sulfonic acid
CAS Number	554-18-7
PubChem CID	71505
ChemSpider	64579
UNII	I6RLN7D44F
CompTox Dashboard (EPA)	DTXSID10873666
Chemical and physical data
Formula	C24H36N2O18S3
Molar mass	736.73 g·mol
3D model (JSmol)	Interactive image
SMILES ..S(=O)(=O)(Nc1ccc(cc1)S(=O)(=O)c2ccc(N(S()(=O)=O)(O)(O)(O)(O)CO)cc2)(O)(O)(O)(O)CO
InChI InChI=1S/C24H36N2O18S3.2Na/c27-9-15(29)17(31)19(33)21(35)23(46(39,40)41)25-11-1-5-13(6-2-11)45(37,38)14-7-3-12(4-8-14)26-24(47(42,43)44)22(36)20(34)18(32)16(30)10-28;;/h1-8,15-36H,9-10H2,(H,39,40,41)(H,42,43,44);;/q;2*+1/p-2/t15-,16-,17-,18-,19+,20+,21-,22-,23+,24+;;/m1../s1 Key:NLLGJEMIZSAJFN-XRAGNMTMSA-L
(what is this?)  (verify)

Promin, or sodium glucosulfone is a sulfone drug that was investigated for the treatment of malaria, tuberculosis and leprosy. It is broken down in the body to dapsone, which is the therapeutic form.

History

The first synthesis of Promin is sometimes credited to Edward Tillitson and Benjamin F. Tullar of Parke, Davis, & Co. pharmaceuticals in August 1937. However, although Parke-Davis did in fact synthesize the compound, it seems certain that they were not the first; in cooperation with J. Wittmann, Emil Fromm synthesised various sulfone compounds in 1908, including both dapsone and some of its derivatives, such as promin. Fromm and Wittmann however were engaged on chemical rather than medical work, and no-one investigated the medical value of such compounds until some decades afterwards. The medical evaluation of sulfones was inspired by the discovery of the unprecedented value of synthetic compounds such as sulfonamides in treating microbial diseases. Early investigations yielded disappointing results, but subsequently promin and dapsone proved valuable in treating mycobacterial diseases. They were the first treatments to show more than a glimmer of hope of controlling such infections.

Initially, Promin appeared to be safer than dapsone, so it was further investigated at the Mayo Clinic as a treatment for tuberculosis in a guinea pig model. Because it was already known that leprosy and tuberculosis were both caused by mycobacteria (Mycobacterium leprae and Mycobacterium tuberculosis, respectively), Guy Henry Faget of the National Leprosarium in Carville, Louisiana, requested information about the drug from Parke-Davis. They, in turn, informed him of the work being done on leprosy in rats by Edmund Cowdry at the Washington University School of Medicine. His successful results, published in 1941, convinced Faget to begin human studies, both with promin and sulfoxone sodium, a related compound from Abbott Laboratories. The initial trials were on six volunteers, and were then expanded and replicated in different locations. Despite severe side effects that caused the initial tests to be suspended temporarily, the drug was shown to be effective. This breakthrough was reported worldwide, and led to a reduction in the stigma attached to leprosy, and consequent better treatment of patients, at the time still referred to as "inmates", and forbidden from using public transport.

Pharmacology

Promin is heat-stable and water-soluble, and can therefore be heat-sterilized. It can be injected intravenously, and is available in ampules.

Beyond its solubility, however, promin was later found to have no real advantages over the simpler compound dapsone (which is administered in tablet form). Promin and other sulfones can also not be used as substitutes for dapsone when intolerance develops, as this is a general reaction to sulfones, and not specific to dapsone.

Today, the drugs of choice for treating leprosy are dapsone, rifampicin and clofazimine.

References

1. Slater LB (2009). War and disease: biomedical research on malaria in the twentieth century. New Brunswick, N.J: Rutgers University Press. p. 102. ISBN 978-0-8135-4438-0.
2. Lilienfeld D, Schneider D (2011). Public Health: The Development of a Discipline. Vol. 2 Twentieth-Century Challenges. New Brunswick, N.J: Rutgers University Press. p. 351. ISBN 978-0-8135-5009-1.
3. Faget GH, Pogge RC, Johansen FA, Dinan JF, Prejean BM, Eccles CG (November 1943). "The Promin Treatment of Leprosy". Public Health Reports. 58 (48). Washington, D.C.: 1729–1741. doi:10.2307/4584691. JSTOR 4584691. PMC 2017027. PMID 19315949.
4. Faget GH, Pogge RC, Johansen FA, Dinan JF, Prejean BM, Eccles CG (1966). "Reprint: The promin treatment of leprosy. A progress report". International Journal of Leprosy and Other Mycobacterial Diseases. 34 (3): 298–310. PMID 5950351.
5. McDougall AC (June 1979). "Dapsone". Clinical and Experimental Dermatology. 4 (2): 139–42. doi:10.1111/j.1365-2230.1979.tb01608.x. PMID 498567.
6. Johansen EA. "Current Data on Promin Therapy; reprinted in The Star October-December 2003" (PDF).
7. ^ Wozel G (1989). "The story of sulfones in tropical medicine and dermatology". International Journal of Dermatology. 28 (1): 17–21. doi:10.1111/j.1365-4362.1989.tb01301.x. PMID 2645226. S2CID 30991934.
8. Desikan KV (January 2003). "Multi-drug Regimen in Leprosy and its impact on Prevalence of the Disease". Medical Journal, Armed Forces India. 59 (1): 2–4. doi:10.1016/S0377-1237(03)80092-8. PMC 4925770. PMID 27407445.
9. ^ Sneader W (2005). Drug discovery: a history. New York: Wiley. ISBN 978-0-471-89979-2.
10. Tayman J (2006). The Colony. Simon and Schuster. p. 252. ISBN 0-471-89979-8.
11. "Hope for Lepers". Time Magazine. 30 December 1946. Retrieved 22 July 2011.
12. ^ Singh R (2002). Synthetic Drugs. Mittal Publications. p. 291. ISBN 978-81-7099-831-0.
13. Clinical Leprosy. Jaypee Brothers Medical Publishers (P) Ltd. 2004. ISBN 978-81-8061-283-1.
14. Textbook Of Pharmacology. Elsevier India Pvt. Ltd. 2008. pp. X–87. ISBN 978-81-312-1158-8.
15. Ravina E, Kubinyi H (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons. p. 80. ISBN 978-3-527-32669-3.

• Anilines
• Benzosulfones
• Dihydropteroate synthetase inhibitors
• Antileprotic drugs
• Prodrugs